CorRen Medical Inc.

1 in 20 Americans over age 50 has peripheral artery disease, but many mistake their leg pain for arthritis or a normal part of aging. Ask your doctor about PAD. Early detection and treatment can help prevent complications such as amputation.

Exciting news! CorRen Medical, Inc. has been selected as a finalist for the American Heart Association’s EmPOWERED to Serve Business Accelerator? program, focused on tackling health disparities. We’re proud to be one of 11 finalists chosen from nearly 300 applicants nationwide. ?Each day, over 400 Americans lose a limb due to Peripheral Artery Disease (PAD), which disproportionately affects underserved communities. The AHA recommends annual PAD testing for 70 million Americans, but only 20% are currently tested. This gap exists due to outdated tools that make testing complex and time-consuming. At CorRen, we’re closing this gap with our AI-powered ultrasound technology, making PAD testing faster, easier, and more accessible. This program strengthens our commitment to advancing health equity, and we’re excited to drive meaningful change!

CorRen Medical is pleased to announce the addition of Melanie Hess to its Board of Directors. Melanie brings 25 years of experience in the medical device industry, with a strong focus on regulatory strategy, quality systems, and global compliance. Her extensive career includes leadership roles at Endogenex, Osprey Medical, American Medical Systems, Endo Pharmaceuticals, and St. Jude Medical. She has played a key role in achieving commercial approvals with regulatory authorities globally and has led quality and compliance initiatives across multiple organizations. Prior to her work in the medical device industry, Melanie spent 8 years as a medical and surgical intensive care nurse. She holds a BSN from the University of Minnesota and an MBA from the University of Phoenix. We look forward to her valuable contributions as we continue to advance our mission of preventing lower limb amputations by making Peripheral Artery Disease testing universal and assessable.

We’re excited to announce that CorRen Medical has been selected to participate in the Creative Destruction Lab (CDL) Health and Wellness program. At CorRen, our mission is to advance the early diagnosis of peripheral artery disease (PAD) while it is most treatable. With CDL’s support, we aim to accelerate our vision of preventing limb loss by making PAD testing universal and accessible. ? The CDL Health program offers startups access to a network of seasoned entrepreneurs, clinicians, engineers, and investors, helping refine business strategies and identify growth opportunities. This aligns with our goal of improving the quality, speed, and accessibility of PAD testing. We look forward to collaborating with experts as we continue to make strides in PAD prevention, diagnosis, and treatment.

We are excited to announce the addition of Rodney Houfburg as VP of Research and Development to our CorRen Medical team!?Rod has a broad range of executive engineering leadership experience in both publicly held and private venture backed medical device companies. He has a thirty plus (30+) year proven track record of developing multiple successful medical device implant and instrumentation systems from initial concept through final commercialization in early-stage start-up to mature organizations. Rod has a diverse medical device background, including orthopedics, spine and cardiology.

Mike McCormick and David Lerner will be attending BETA’s demo day along with startup founders, investors, and engineers to celebrate the #beta spring cohort finalists. See you June 10!

Proud to share that CorRen is a MN Cup semifinalist! We are honored to have been chosen to move on to the next level of this distinguished startup competition. Read more about this opportunity and our semifinalist peers at https://lnkd.in/e5HfFaUE #mncup #semifinalist #startupcompetition #medicaldevicestartup

We are thrilled to share a deeper drive into the 5 exceptional global startups that will present at our Trans Atlantic Angel Conference Demo Day Event next week. Our current program's Angel Investors (TAAC#5) will make a $125,000 investment in the selected winning startup. Let us introduce the first startup, CorRen Medical, Inc. (https://correnmedical.com/) About us… Located in the heart of Minnesota’s Medical Alley, CorRen Medical is an early-stage device company committed to the diagnosis and treatment of Peripheral Artery Disease (PAD) and related vascular problems. Their proprietary ultrasound technology sets a new standard to improve outcomes and reduce cost of care for millions of patients. What makes us different… CorRen is developing an autonomous, hands-free Ankle Brachial Index (ABI) test for detecting PAD. The worldwide market potential for ABI testing equipment stands at $1.6B. Existing ABI testing methods face challenges of complexity and time constraints. CorRen's UltraSense is designed to bridge this gap, providing an accurate, user-friendly, and reimbursable solution that has the potential to revolutionize PAD diagnosis and treatment. They utilize proprietary AI technology and clinical analysis algorithms to inform therapy and improve patient outcomes. How we plan to change the world… With UltraSense, they aim to combat PAD, the second leading cause of morbidity in the Western world. By 2050, it is projected to afflict 24 million Americans. You can join us for the Demo Day next Tuesday and see all finalists deliver their final presentation to secure funding from our Angels. Book your place today; https://shorturl.at/g2TAz Astghik Zakharyan John Sechrest Sofia-Cristina V. CorRen Medical Inc. Mike McCormick Due diligence team - Nicholas Smit Ferdinand Pons Margaret Baburyan Bianca Tipei

Thank you BETA for the opportunity to present our novel #ultrasound technology for the detection of #PAD. We are honored to have been awarded 2nd place amongst such a talented group. #medicaldevicestartup #betashowcase #PADsolutions #AItechnology

Recent achievement: CorRen Medical proudly secured its place among the top 6 finalists of the Seattle Angel Conference from a pool of 117 promising startups! CorRen’s journey, from a concise 1-minute pitch to a compelling 10-minute presentation, culminated in an unforgettable night at the finals. This experience has been invaluable, shaping CorRen's resilience and determination for the road ahead. Gratitude to all who have championed us on this remarkable journey. #seattleangelconference #medicaldevice #startup